Literatur
-
1
Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T.
heparin-induced thrombocytopenia in hemodialysis patients.
Am J Kidney Dis.
1996;
28
(1)
82-85
-
2
Greinacher A, Zinn S, Wizeman U, Birk W.
Heparin-induced antibodies as a risk factor for thromboembolism and hemorrhage in patients undergoing chronic hemodialysis.
Lancet.
1996;
348
764
-
3
John G, Shebabi Y, Mudaliar Y.
Use of a low molecular weight preparation of heparin Org 10172 (Lomoparan) in the critically ill.
Anaesth Intensive Care.
1991;
19
588-591
-
4
Lindhoff-Last E, Betz C, Bauersachs R.
Use of a low-molecular weight heparinoid (danaparoid-sodium) for continuous renal replacement therapy in intensive care patients.
Clin Appl Thrombosis/Hemostasis.
2001;
7
(4)
300-304
-
5
Lindhoff-Last E, Eichler P, Stein M, Plagemann J, Gerdsen F, Wagner R, Ehrly A M, Bauersachs R.
A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery.
Thromb Res.
2000;
97
387-393
-
6
Warkentin T E, Levine M N, Hirsh J, Horsewood P, Roberts R S, Tech M, Gent M, Kelton J G.
Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin.
New Engl J Med.
1995;
332
1330-1335
-
7
Mangnani H N.
Orgaran (danaparoid natrium) use in the syndrome of heparin-induced thrombocytopenia.
Platelets.
1997;
8
74-81
-
8 Fischer K G. Hemodialysis in heparin-induced thrombocytopenia. New York; Marcel Dekker 2000: 339-354
Dr. Edelgard Lindhoff-Last
Medizinische Klinik I, Schwerpunkt Angiologie,
Johann-Wolfgang-Goethe-Universität Frankfurt
Theodor-Stern-Kai 7
60590 Frankfurt am Main
